IGF2BP2-mediated m6A modifies SLC7A11 to regulate proliferation and ferroptosis in non-small cell lung cancer cells
Advances in Clinical and Experimental Medicine · 2025
DOI: 10.17219/acem/200588 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Clinical and Experimental Medicine, 2025. Verfasst von Bo Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Yingkou Central Hospital, China. Hauptthemen laut MEDLINE: Ferroptosis, Amino Acid Transport System y+, RNA-Binding Proteins, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
BACKGROUND: Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) is implicated in various cancers, but its role in modulating ferroptosis and tumor cell behavior in non-small cell lung cancer (NSCLC) remains unclear. OBJECTIVES: This study aimed to investigate how IGF2BP2-mediated N6-methyladenosine (m6A) modification of solute carrier family 7 member 11 (SLC7A11) affects ferroptosis and NSCLC cell viability. MATERIAL AND METHODS: NSCLC H1299 cells were transfected with either IGF2BP2 or SLC7A11 plasmids and corresponding siRNAs. Expression levels of IGF2BP2, SLC7A11 and ferroptosis markers were analyzed using reverse transcription real-time quantitative polymerase chain reaction (RT-qPCR) and western blot. Cell viability was assessed using the Cell Counting Kit-8 (CCK-8) assay. Reactive oxygen species (ROS) and lipid peroxidation levels were measured with flow cytometry and biochemical kits. The RNA immunoprecipitation (RIP) and mRNA stability assays were utilized to explore the interaction between IGF2BP2 and SLC7A11. RESULTS: IGF2BP2 expression was significantly upregulated in H1299 cells. Overexpression of IGF2BP2 enhanced cell viability and decreased ferroptosis, whereas its knockdown resulted in reduced cell viability and increased ferroptotic activity. IGF2BP2 enhanced SLC7A11 mRNA stability through m6A modification, and SLC7A11 overexpression reversed the effects of IGF2BP2 knockdown. This interaction increased cell viability and reduced ROS and lipid peroxidation. CONCLUSIONS: IGF2BP2 plays a critical role in NSCLC by stabilizing SLC7A11 mRNA via m6A modification, promoting cell proliferation and suppressing ferroptosis. Targeting the IGF2BP2-SLC7A11 axis may offer a promising therapeutic strategy for NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Yingkou Central Hospital, China.
- Department of Medical Oncology, Yingkou Central Hospital, China.
- Department of Gastroenterological Surgery, Peking University International Hospital, Beijing, China.
Zitieren
APA
Li, B., Li, S. Y., & Yan, Y. C. (2025). IGF2BP2-mediated m6A modifies SLC7A11 to regulate proliferation and ferroptosis in non-small cell lung cancer cells. Advances in Clinical and Experimental Medicine. https://doi.org/10.17219/acem/200588
Vancouver
Li B, Li SY, Yan YC. IGF2BP2-mediated m6A modifies SLC7A11 to regulate proliferation and ferroptosis in non-small cell lung cancer cells. Advances in Clinical and Experimental Medicine. 2025. doi:10.17219/acem/200588
BibTeX
@article{Li2025,
author = {Li, Bo and Li, Si-Ying and Yan, Yi-Chao},
title = {IGF2BP2-mediated m6A modifies SLC7A11 to regulate proliferation and ferroptosis in non-small cell lung cancer cells},
journal = {Advances in Clinical and Experimental Medicine},
year = {2025},
doi = {10.17219/acem/200588}
}
EUVIMED